Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(1 site)
United States
The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York